There has been opposing reports regarding the ability of PPARγ to effect tumor progression as both agonists and antagonists have demonstrated anti-tumorigenic properties.27 PPARγ agonists have shown potential anti-glioma effects.10 As low expression of CIDEA in glioma is concomitant with elevated levels of PPARγ and HIF-1α, this study was undertaken to understand the (i) role of PPARγ and HIF-1α in maintaining the low basal expression of CIDEA in GBM, and (ii) the effect of CIDEA overexpression on glioma cell survival. The gene discussed is PPARG; the disease is central nervous system cancer.